US drug regulator OKs obesity drug that helped cut weight 15% | Daily Sabah – Daily Sabah

U.S. drug regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the country.
The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisks diabetes drug semaglutide.
In company-funded studies, participants taking Wegovy had an average weight loss of 15%, about 34 pounds (15.3 kilograms). Participants lost weight steadily for 16 months before plateauing. In a comparison group getting dummy shots, the average weight…

Click here to view the original article.